NASDAQ$PLRX
Pliant Therapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Pliant Therapeutics reported first quarter 2021 financial results and provided a corporate update.
Pliant Therapeutics reported a net loss of $22.9 million for the first quarter of 2021, compared to a net income of $11.0 million for the prior-year quarter. Research and development expenses increased to $18.5 million, and general and administrative expenses rose to $6.6 million. As of March 31, 2021, the company had $264.1 million in cash, cash equivalents, and short-term investments.
- PLN-74809 Phase 2a PET imaging trial preliminary data expected in the first half 2021.
- PLN-74809 Phase 2a INTEGRIS trial in idiopathic pulmonary fibrosis (IPF) continued to build momentum, currently on track to complete enrollment by the end of 2021.
- PLN-74809 Phase 2a INTEGRIS trial in primary sclerosing cholangitis (PSC) continued to advance, currently on track to complete enrollment in the first half 2022.
- Successful completion of PLN-1474 Phase 1 trial and transfer of PLN-1474 to Novartis.
Headline financials
Revenue & EPS history
Pliant Therapeutics · Revenue · Quarterly
$2.17M
Forward guidance
The Company believes it has sufficient funds to meet its operating and capital requirements into 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
-1.8%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-4.2%
Avg return
30 days after
36%
9 / 25 earnings
Positive
+12.1%
Q3 2020
Best reaction
-11.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.8% | -4.2% | -4.2% | |
| Q3 2025 | +3.3% | +17.6% | -20.9% | |
| Q1 2025 | -1.5% | -2.9% | -1.4% | |
| Q4 2024 | -11.7% | +17.4% | -5.1% | |
| Q3 2024 | -4.5% | -12.0% | -6.4% | |
| Q2 2024 | -6.5% | -9.6% | -1.8% | |
| Q1 2024 | -1.4% | -1.2% | -13.4% | |
| Q4 2023 | -7.8% | -4.8% | -13.4% | |
| Q3 2023 | -8.0% | -12.4% | -2.7% | |
| Q2 2023 | +3.4% | -0.9% | -9.5% | |
| Q1 2023 | +4.2% | -0.0% | +3.0% | |
| Q4 2022 | -10.9% | -9.4% | -17.6% | |
| Q3 2022 | -6.5% | -6.7% | -14.5% | |
| Q2 2022 | +11.9% | +12.6% | +6.2% | |
| Q1 2022 | -6.8% | -1.8% | +40.5% | |
| Q4 2021 | +3.7% | -9.9% | -26.6% | |
| Q3 2021 | -4.0% | -3.2% | -17.9% | |
| Q2 2021 | -6.5% | -12.4% | -15.7% | |
| Q1 2021 | -0.1% | -14.7% | -3.1% | |
| Q4 2020 | +4.6% | +2.5% | -19.9% | |
| Q3 2019 | +12.1% | +9.9% | +21.2% | |
| Q3 2020 | +12.1% | +9.9% | +21.2% | |
| Q2 2020 | -8.5% | -8.2% | -1.2% | |
| Q4 2019 | -8.5% | -8.2% | -1.2% | |
| Q2 2019 | -8.5% | -8.2% | -1.2% | |
| Q1 2020 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro